Chihiro Shimazaki

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Venues

Cancer immunology, immunotherapy : CII

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Chihiro Shimazaki, Saori Matsui-Maegawa, Yayoi Kimoto-Matsumura, Saeko Ota-Kuwabara, Daisuke Ide, Shin-Ichi Fuchida, Mayumi Hatsuse
The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis. British journal of haematology (2023)

Chihiro Shimazaki.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Chihiro Shimazaki